An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma
Treatment with MabThera/Rituxan as per locally approved China package insert
Documented patient with medical records
You may not be if
Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma
Clareo Health | An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
